---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-017445"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-25T00:07:24.053098+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Provectus provides annual meeting update on clinical and corporate activities; no specific results disclosed

## Summary
- Annual stockholders meeting held on June 22, 2022.
- Presentation covered clinical development, regulatory, drug discovery, manufacturing, IP, and business development.
- No earnings, revenue, or clinical trial data were reported in the 8-K or exhibit summary.
- Presentation slides furnished as Exhibit 99.1, not filed or incorporated by reference.

## SEC filing metadata
- accession: 0001493152-22-017445
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315222017445/0001493152-22-017445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315222017445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-017445
- JSON: https://secwatch.observer/filing/0001493152-22-017445.json
- Plain text: https://secwatch.observer/filing/0001493152-22-017445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.